Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2025)

Historic Long-Term Deferred Tax for Ironwood Pharmaceuticals (IRWD) over the last 5 years, with Q3 2025 value amounting to $101.7 million.

  • Ironwood Pharmaceuticals' Long-Term Deferred Tax fell 4513.43% to $101.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.7 million, marking a year-over-year decrease of 4513.43%. This contributed to the annual value of $144.2 million for FY2024, which is 3206.89% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Long-Term Deferred Tax of $101.7 million as of Q3 2025, which was down 4513.43% from $129.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $337.8 million for Q2 2021, and its period low was $101.7 million during Q3 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Long-Term Deferred Tax value was $250.8 million (recorded in 2023), while the average stood at $240.9 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Long-Term Deferred Tax crashed by 510.54% in 2022, and later tumbled by 4513.43% in 2025.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Long-Term Deferred Tax stood at $333.3 million in 2021, then dropped by 14.89% to $283.7 million in 2022, then fell by 25.15% to $212.3 million in 2023, then tumbled by 32.07% to $144.2 million in 2024, then decreased by 29.5% to $101.7 million in 2025.
  • Its last three reported values are $101.7 million in Q3 2025, $129.5 million for Q2 2025, and $143.6 million during Q1 2025.